Immatics (IMTX) Financials: Revenue & Earnings
IMTX$7.40+0.05 +0.68%
$1.11B
Market Cap
-4.10
P/E
—
Forward P/E
46
Score
Immatics (IMTX) Financials: Revenue & Earnings
IMTX price $7.40 +0.05 +0.68%
- Ticker
- IMTX
- Price
- $7.40
- Change
- +0.05 +0.68%
- Market cap ?
- $1.11B
- P/E ?
- -4.10
- Dividend yield ?
- 0.00%
- Beta ?
- 1.36
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 46
- Value
- 55
- Quality
- 32
- Growth
- 50
Stocklytics score rationale: value 55, quality 32, growth 50.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 3770000 | 18449000 | 31253000 | 34763000 | 172831000 | 53997000 | 155835000 | 48266000 |
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio…
Earnings and financials
Immatics N.V. (IMTX) trades at $7.40, with a market cap of $1.11B and a trailing P/E of -4.10. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 3770000 | 18449000 | 31253000 | 34763000 | 172831000 | 53997000 | 155835000 | 48266000 |
Insights · Dividends · Forecast · Financials · Learn